1466 related articles for article (PubMed ID: 21752941)
1. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
2. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
[TBL] [Abstract][Full Text] [Related]
3. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
[TBL] [Abstract][Full Text] [Related]
4. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
6. Constitutively active heat shock factor 1 enhances glucose-driven insulin secretion.
Uchiyama T; Tomono S; Utsugi T; Ohyama Y; Nakamura T; Tomura H; Kawazu S; Okajima F; Kurabayashi M
Metabolism; 2011 Jun; 60(6):789-98. PubMed ID: 20817212
[TBL] [Abstract][Full Text] [Related]
7. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
9. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
10. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
[TBL] [Abstract][Full Text] [Related]
11. Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors.
Tuo Y; Feng DD; Wang DF; Sun J; Li SB; Chen C
Clin Exp Pharmacol Physiol; 2012 May; 39(5):423-8. PubMed ID: 22332921
[TBL] [Abstract][Full Text] [Related]
12. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
[TBL] [Abstract][Full Text] [Related]
13. Anti-diabetic effects of Centratherum anthelminticum seeds methanolic fraction on pancreatic cells, β-TC6 and its alleviating role in type 2 diabetic rats.
Arya A; Looi CY; Cheah SC; Mustafa MR; Mohd MA
J Ethnopharmacol; 2012 Oct; 144(1):22-32. PubMed ID: 22954496
[TBL] [Abstract][Full Text] [Related]
14. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
Araki T; Hirayama M; Hiroi S; Kaku K
Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
16. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR
BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.
Wente W; Efanov AM; Brenner M; Kharitonenkov A; Köster A; Sandusky GE; Sewing S; Treinies I; Zitzer H; Gromada J
Diabetes; 2006 Sep; 55(9):2470-8. PubMed ID: 16936195
[TBL] [Abstract][Full Text] [Related]
18. New insights into fatty acid modulation of pancreatic beta-cell function.
Haber EP; Procópio J; Carvalho CR; Carpinelli AR; Newsholme P; Curi R
Int Rev Cytol; 2006; 248():1-41. PubMed ID: 16487789
[TBL] [Abstract][Full Text] [Related]
19. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
